Heavy chain only antibodies to ANG-2

Patent metadata

Field	Value
Publication number	US-11046756-B2
Application number	US-201916385384-A
Country	US
Kind code	B2
Filing date	Apr 16, 2019
Priority date	Jul 29, 2015
Publication date	Jun 29, 2021
Grant date	Jun 29, 2021

Abstract

Disclosed herein are monospecific HCAb antibodies with antigen-binding specificity to ANG-2 and bispecific antibodies with antigen-binding specificities to ANG-2 and VEGF or PDGF.

First claim

What is claimed is:

1. A method of treating age-related macular degeneration comprising administering to a subject in need thereof a heavy chain antibody (HCAb) with an antigen-binding specificity for ANG-2, wherein the HCAb comprises three complementarity determining regions (CDR), wherein:
the first CDR (CDR1) comprises SEQ ID NO:12;
the second CDR (CDR2) comprises SEQ ID NO:14; and
the third CDR (CDR3) comprises one of SEQ ID NOs:16, 28, or 31.

2. The method of claim 1 , wherein CDR3 comprises SEQ ID NO. 16.

3. The method of claim 1 , wherein CDR3 comprises SEQ ID NO:28.

4. The method of claim 1 , wherein CDR3 comprises SEQ ID NO:31.

5. A method of treating age-related macular degeneration comprising administering to a subject in need thereof a heavy chain antibody (HCAb) with an antigen-binding specificity for ANG-2, wherein the HCAb comprises three CDRs, wherein CDR1 comprises SEQ ID NO:32, CDR2 comprises SEQ ID NO:33, and CDR3 comprises SEQ ID NO:34.

6. A method of treating age-related macular degeneration comprising administering to a subject in need thereof a heavy chain antibody (HCAb) with an antigen-binding specificity for ANG-2, wherein the HCAb comprises three CDRs, wherein CDR1 comprises SEQ ID NO:35, CDR2 comprises SEQ ID NO:36, and CDR3 comprises SEQ ID NO:37.

7. The method of claim 1 , wherein the age-related macular degeneration is wet age-related macular degeneration or neovascular age-related macular degeneration.

8. The method of claim 7 , wherein the wet age-related macular degeneration or the neovascular age-related macular degeneration is associated with aging.

9. The method of claim 7 , wherein the wet age-related macular degeneration or the neovascular age-related macular degeneration is caused by severe myopia.

10. The method of claim 7 , wherein the wet age-related macular degeneration or the neovascular age-related macular degeneration is caused by intraocular infections such as histoplasmosis.

11. The method of claim 1 , wherein the age-related macular degeneration is dry age-related macular degeneration or non-neovascular age-related macular degeneration.

12. The method of claim 11 , wherein the dry age-related macular degeneration or the non-neovascular age-related macular degeneration is caused by distortion, pigmentation, or thinning of the retina.

13. The method of claim 1 , wherein the heavy chain antibody (HCAb) is administered in a sustained release formulation.

14. The method of claim 13 , wherein the heavy chain antibody (HCAb) is released into the vitreous over a 3-6-month period.

Assignees

• Allergan Inc

Inventors

• Liang Yanbin
• Gil Daniel W

Classifications

• C07K2317/526

  CH3 domain · CPC title

• C07K2317/76

  Antagonist effect on antigen, e.g. neutralization or inhibition of binding · CPC title

• C07K16/22 Primary

  against growth factors {; against growth regulators} · CPC title

• C07K2317/569

  Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody® · CPC title

• C07K2317/565

  Complementarity determining region [CDR] · CPC title